Miltenyi, 130-091-379, Blood Dendritic Cell Isolation Kit II, human

Detailed separation procedure
The isolation is performed in a two-step procedure. First, B cells and monocytes are magnetically labeled and depleted using a cocktail of CD19 and CD14 MicroBeads. Subsequently, the pre-enriched dendritic cells in the non-magnetic flow-through fraction are magnetically labeled and enriched using a cocktail of antibodies against the dendritic cell markers CD304 (BDCA-4/Neuropilin-1), CD141 (BDCA-3), and CD1c (BDCA-1). The highly pure enriched cell fraction comprises plasmacytoid dendritic cells, CD1c (BDCA-1)+ type-1 myeloid dendritic cells (MDC1s), and CD1c (BDCA-1)- CD141 (BDCA-3)bright type-2 myeloid dendritic cells (MDC2s).
B cells and monocytes are depleted in advance because a subpopulation of B cells expresses CD1c (BDCA-1), and monocytes express CD141 (BDCA-3) at low levels.

Downstream applications
Dendritic cells isolated by MACS® Technology are, for example, suitable for in vitro induction of primary T cell responses.

Columns
For the first magnetic separation (depletion): LD, CS, D, or autoMACS® Columns. For the second magnetic separation (positive selection): MS, LS, or autoMACS Columns.

Overview
The Blood Dendritic Cell Isolation Kit II is a magnetic labeling system for the concurrent isolation of plasmacytoid and myeloid dendritic cells from human PBMCs.